EX-FILING FEES

Exhibit 107

Calculation of Filing Fee Table

424(b)(2)

(Form Type)

GSK plc

GlaxoSmithKline Capital Inc.

GlaxoSmithKline Capital plc

(Exact Name of Registrant as Specified in its Charter)

Table 1: Newly Registered and Carry Forward Securities

(1)

Security
Type

Security Class
Title

Fee
Calculation
or Carry
Forward
Rule

Amount
Registered

Proposed
Maximum
Offering
Price Per
Unit

Maximum
Aggregate
Offering
Price

Fee
Rate

Amount of
Registration
Fee

Carry
Forward
Form
Type

Carry
Forward
File
Number

Carry
Forward
Initial
Effective
date

Filing Fee
Previously
Paid In
Connection
with Unsold
Securities to
be Carried
Forward

Newly Registered Securities

Fees To Be Paid

Fees

Previously

Paid

Carry Forward Securities

Carry

Forward Securities

Debt

Debt Securities

Rule 415(a)(6)

$10,000,000,000

(2)

—

$2,600,000,000

(2)

—

(2)

F-3

333-254756,

333-254756-01

and

333-254756-02

March 15, 2023

$1,102,000

(

Total Offering Amounts

$2,600,000,000

(1)

Total Fees Previously Paid

—

Total Fee Offsets

—

Net Fee Due

(2)

(1)

The prospectus supplement to which this Exhibit is attached is a final prospectus for the related

offering

(the “Prospectus”) of 4.500% Notes due 2030 and 4.875% Notes due 2035 to be issued by GlaxoSmithKline Capital Inc. (the “GSK Capital Inc. Notes”), and 4.315% Notes due 2027 and Floating Rate Notes due 2027 to be issued by GlaxoSmithKline Capital plc (the “GSK Capital plc Notes” and, together with the GSK Capital Inc. Notes, the “Notes”). The Notes will be fully and unconditionally guaranteed by GSK plc (the “Guarantees”). The maximum aggregate offering price of the Notes is $2,600,000,000. Pursuant to Rule 457(n), no separate fee for the Guarantees is payable.

(2)

The Notes being offered under this prospectus supplement include unsold securities previously registered pursuant to a Registration Statement on Form

F-3

(File Nos.

333-254756,

333-254756-01

and

333-254756-02)

filed with the Securities and Exchange Commission on March 26, 2021, as amended by Post-Effective Amendment No. 1 filed on March 10, 2023 and declared effective on March 15, 2023 (the “Prior Registration Statement”). As of the date of this prospectus supplement, the registrants have not sold an aggregate of $10,000,000,000 of the securities registered pursuant to the Prior Registration Statement (the “Unsold Securities”), representing $1,102,000 in registration fees of such Unsold Securities under the Prior Registration Statement. In accordance with Rule 415(a)(6) under the Securities Act of 1933, as amended, $2,600,000,000 aggregate off

eri

ng price of the Unsold Securities are being carried forward and included in this prospectus supplement. Accordingly, no registration fee is being paid at this time. Pursuant to Rule 415(a)(6), this “Calculation of Filing Fee” table shall be deemed to update the “Calculation of Filing Fee” table in the current registration statement on Form

F-3ASR

filed with the Securities and Exchange Commission on March 24, 2024 (File Nos.

333-278205,

333-278205-01

and

333-278205-02))

to continue the offering of Unsold Securities initially registered under the Prior Registration Statement.